Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Breast cancer
Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer
The NCI trial is evaluating ASTX727—combining decitabine (a hypomethylation agent) with cedazuridine (a cytidine deaminase inhibitor)—in combination with paclitaxel and pembrolizumab across 1st to 4th line metastatic…
NCT05673200 - New trial
Breast cancer
Feasibility Pilot of Topical Azelaic Acid in Breast Cancer Radiation
Virginia Commonwealth University is assessing the feasibility of twice-daily application of azelaic acid—an investigational anti-inflammatory natural product—in breast cancer patients undergoing concurrent…
NCT06966388 - New trial
Brain and CNS tumors
Phase I Trial of CAR T Cells Targeting B7-H3 in Recurrent Glioblastoma
UNC Lineberger is evaluating the safety of intraventricular infusion of investigational B7-H3 directed CAR T cells in patients with recurrent or refractory glioblastoma, with dose-finding in subjects following…
NCT05366179 - New trial
Brain and CNS tumors
Phase II Trial in Glioblastoma: Accelerated RT with Temozolomide Evaluation
Mayo Clinic is comparing short course stereotactic accelerated radiotherapy combined with temozolomide against standard course RT in glioblastoma patients to determine non-inferiority. The trial features integrated…
NCT05781321 - New trial
Brain and CNS tumors
Feasibility of 5-ALA for Fluorescence-Guided Surgery in Pediatric Brain Tumors
This University of Pittsburgh study is assessing 5-ALA—a small molecule that induces tumor fluorescence—for its feasibility in improving tumor visualization during resection in pediatric patients (ages 2 to 18) with…
NCT06907485 - New trial
Lymphoma
Phase 2 Trial of Glofitamab (CD20/CD3 Bispecific) in MRD+ LBCL
MD Anderson is recruiting patients with large B-cell lymphoma who achieved CR after first-line therapy but remain MRD-positive to assess the safety and recurrence prevention potential of glofitamab, a CD20 and CD3…
NCT06670105 - New trial
Bladder and urothelial cancer
Phase II Trial of Herpes Virus T3011 Injection (IL‑12 & PD‑1 Mab) in High-Risk NMIBC
ImmVira Pharma is spearheading a phase II study to assess the tolerability, safety, and early efficacy of T3011—an oncolytic HSV‑1 engineered to express IL‑12 and a PD‑1 monoclonal antibody—in patients with…
NCT06971614 - New trial
Colorectal cancer
Phase I Trial of CA-4948 (IRAK4/FLT3 Inhibitor) with FOLFOX and Bevacizumab in Metastatic Colorectal Cancer
The NCI is evaluating the safety and optimal dosing of CA-4948—an investigational IRAK4 and FLT3 inhibitor—in combination with FOLFOX plus bevacizumab as a first-line treatment for metastatic colorectal cancer.
NCT06696768 - New trial
Thyroid cancer
Phase II Study of Lenvatinib & Pembrolizumab (PD-1) in Unresectable Anaplastic Thyroid Cancer
M.D. Anderson is evaluating the combination of lenvatinib, a multikinase inhibitor, with pembrolizumab, a PD-1 monoclonal antibody, in patients with stage IVB unresectable or stage IVC metastatic anaplastic thyroid…
NCT04171622 - New trial
Other blood cancers and transplant
Phase I Daratumumab (CD38) Immunotherapy in High-Risk T-ALL/T-LLy
New York Medical College is sponsoring a Phase I trial to assess the safety of daratumumab—a CD38-directed monoclonal antibody—administered after TBI-based myeloablative conditioning and allogeneic HCT in children,…
NCT04972942 - New trial
Other blood cancers and transplant
Phase 2 Study of Blinatumomab (CD19 Targeted) and Venetoclax (BCL2 Inhibitor) in KMT2A-Altered Infant ALL
This trial evaluates the safety and efficacy of adding CD19-directed blinatumomab and BCL2 inhibitor venetoclax to standard chemotherapy in infants with newly diagnosed ALL with either KMT2A rearrangement or…
NCT06317662 - New trial
Colorectal cancer
Phase II NALIRIFOX in Advanced Unresectable Small Bowel Tumors (MMRp/MSS)
This H. Lee Moffitt Cancer Center phase II outpatient study is evaluating NALIRIFOX—combining nanoliposomal irinotecan (a topoisomerase I inhibitor), oxaliplatin, 5-FU, and leucovorin—in advanced unresectable small…
NCT06835387 - New trial
Pancreatic cancer
Pilot Study of Tamoxifen (Estrogen Receptor Inhibitor) in Pre-Invasive Pancreas MCN
The University of Nebraska is conducting an open‐label pilot study enrolling up to 15 participants with pancreatic MCN who won't undergo immediate resection, to assess the feasibility of 20mg daily tamoxifen over 6…
NCT06320990 - New trial
Head and neck cancer
Phase II De-escalation Trial for HPV/p16+ Oropharyngeal Cancer
Georgetown is evaluating whether a lower-than-standard, neck-only radiation regimen (50Gy in 25 fractions via IMRT or proton beam therapy) leads to tumor control comparable to historical outcomes in favorable-risk,…
NCT06554158 - Trial result
Non-small cell lung cancer
Cemiplimab Boosts Survival in NSCLC Patients with Brain Metastases
In this exploratory subgroup analysis of the EMPOWER-Lung 1 study, first-line cemiplimab monotherapy in patients with advanced NSCLC and PD-L1 ≥50% with brain metastases (following radiotherapy) yielded a median…
- Trial result
Non-small cell lung cancer
Alectinib Plus Bevacizumab Yields Impressive 12-Month PFS and 100% ORR in ALK+ NSCLC
In the phase 2 ALEK-B trial, combining alectinib (600 mg BID) with bevacizumab (15 mg/kg) in 41 advanced ALK-rearranged NSCLC patients, including those with brain metastases, resulted in a 97.1% 12-month…
- Trial result
Non-small cell lung cancer
IMpower151 in Metastatic NSqNSCLC: Atezolizumab Combo Falls Short on Primary Endpoint
In this randomized double-blind phase 3 trial conducted in China with 305 chemotherapy-naive metastatic non-squamous NSCLC patients—53% of whom had EGFR+ tumors—the combination of atezolizumab, bevacizumab,…
- Trial result
Breast cancer
Nivolumab Plus Low-Dose Ipilimumab Shows Promise in Hypermutated HER2-Negative Metastatic Breast Cancer
In the phase II NIMBUS trial, HER2-negative metastatic breast cancer (MBC) patients with high tumor mutational burden (TMB ≥9 mut/Mb) received nivolumab and low-dose ipilimumab, achieving an overall objective…
- Trial result
Multiple solid tumors
Pembrolizumab Erases ctDNA in Median 2 Cycles, Boosting 3-Year EFS to 92 % in dMMR/MSI-H Tumors
Phase II neoadjuvant trial NCT04082572 tracked 35 locally advanced dMMR/MSI-H cancers for 3 years: overall EFS/OS were 80% / 94%, but patients who cleared ctDNA after pembrolizumab hit 3-year EFS 92% and OS 100%…
NCT04082572 - Trial result
Prostate cancer
Fusion of Dose-Dense Docetaxel and Radium-223 Delivers Promise for Bone-Dominant CRPC
A phase escalation study in bone-predominant metastatic castration-resistant prostate cancer (CRPC) demonstrated that a dose-dense regimen of docetaxel combined with standard radium-223—with a lead-in cycle and G-CSF…
- Trial result
Sarcoma and GIST
FAZ053 Monotherapy Shines in Rare Sarcomas Despite Combination Setbacks
In this first-in-human, phase I trial, FAZ053—an anti-PD-L1 monoclonal antibody—was evaluated as monotherapy and in combination with spartalizumab in 154 patients with advanced solid tumors. While around half of the…
- Trial result
Multiple myeloma
Daratumumab-Enhanced Regimen Elevates Outcomes in Older NDMM Patients
Pooled data from the GRIFFIN and PERSEUS studies in transplant-eligible patients aged ≥65 years indicate that adding daratumumab to VRd induction/consolidation followed by daratumumab–lenalidomide maintenance…
- Trial result
Acute lymphoblastic leukemia
High Baseline WBC Identifies High-Risk Patients in Ph+ ALL on Chemo-Free Regimen
In this phase II trial investigating frontline ponatinib and blinatumomab in 76 Ph+ ALL patients, a 3-year event-free survival of 78% and overall survival of 88% were observed, with 13% of patients relapsing—most…
- Trial result
Stomach and esophageal cancer
TAP and CPS Scores Show High Concordance in Predicting Outcomes for Tislelizumab-Treated Gastric and Esophageal Cancers
In a pooled analysis of baseline tissue samples from RATIONALE-305, RATIONALE-302, and RATIONALE-306, PD-L1 expression measured by Tumor Area Positivity (TAP) and Combined Positive Score (CPS) demonstrated…
- Trial result
Liver and bile duct cancer
Durvalumab Plus GemCis Delivers Sustained Survival Benefit in Advanced
The 3-year update from the phase III TOPAZ-1 trial shows that durvalumab combined with gemcitabine and cisplatin (GemCis) significantly improved overall survival in advanced biliary tract cancer compared to…
- New trial
Breast cancer
H-ASSIST: Ultra Hypo-fractionated WBI with SIB for Early-Stage Breast Cancer
UNC Lineberger Comprehensive Cancer Center is evaluating a 5-fraction whole breast irradiation regimen with a simultaneous integrated tumor bed boost in early-stage breast cancer and ductal carcinoma in situ to…
NCT06902311 - New trial
Breast cancer
Phase Ib Randomized Open-label Trial of Sacituzumab Govitecan Plus Nivolumab or Sacituzumab Govitecan Plus Nivolumab and Relatlimab as Second-line Therapy for PD-L1 Positive Metastatic Triple Negative Breast Cancer
Yale is conducting an open-label Phase Ib study evaluating two combination regimens—sacituzumab govitecan with nivolumab versus the same agent paired with fixed-dose nivolumab and relatlimab—in PD-L1 positive…
NCT06963905 - New trial
Breast cancer
Phase 1 Study: BGB-21447 Combination Therapy in HR+/HER2- Metastatic Breast Cancer
BeiGene is evaluating the safety and tolerability of BGB-21447—a Bcl-2 inhibitor—in combination with fulvestrant, with or without BGB-43395 (a CDK4 inhibitor), in adults with HR+/HER2- metastatic breast cancer.…
NCT06756932 - New trial
Breast cancer
LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients With Molecular Low-Risk Early-Stage Breast Cancer
This phase III trial is comparing low-dose tamoxifen to standard endocrine therapy (aromatase inhibitors or full-dose tamoxifen) for post-menopausal, hormone-positive, HER2-negative early stage breast cancer, with…
NCT06671912 - New trial
Breast cancer
Phase Ib/II Study: Low Dose Cyclophosphamide with Axatilimab and Retifanlimab in Metastatic TNBC
M.D. Anderson Cancer Center is evaluating the optimal dosing of low dose oral cyclophosphamide in combination with axatilimab (a CSF1R-directed mAb) and standard-dose retifanlimab (a PD-1 mAb) to treat patients with…
NCT06959537
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.